The companies will combine selected compounds resulting in a library of more than 200,000 compounds available for screening against novel targets. MRC will be responsible for screening the libraries, validation and optimization. Both parties retain ownership of their respective compounds and projects chosen for development will trigger option fees with further research and license agreements. Financial terms were not disclosed.
Justin Bryans, MRC Technology’s director of drug discovery, said, “The collaboration with AstraZeneca this far has been very promising. By continuing to work together we will generate more opportunities to translate early stage academic research into potential new therapies.”
Peter Simpson, director of screening sciences, AstraZeneca, said, “Supporting innovative science with leading external partners is at the heart of AstraZeneca’s Open Innovation Strategy. We look forward to continuing our strong collaboration with MRC with a view to further building our portfolio of early target ideas and external drug discovery capabilities.”